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ABSTRACT: Toll-like receptors (TLRs) are vital elements of the mammalian immune system that function by recognizing pathogen-
associated molecular patterns (PAMPs), bridging innate and adaptive immunity. They have become a prominent therapeutic target 
for the treatment of infectious diseases, cancer, and allergies, with many TLR agonists currently in clinical trials or approved as 
immunostimulants. Numerous studies have shown that conjugation of TLR agonists to other molecules can beneficially influence 
their potency, toxicity, pharmacokinetics, or function. The functional properties of TLR agonist conjugates, however, are highly 
dependent on the ligation strategy employed. Here, we review the chemical structural requirements for effective functional TLR 
agonist conjugation. In addition, we provide similar analysis for those that have yet to be conjugated. Moreover, we discuss 
applications of covalent TLR agonist conjugation and their implications for clinical use. 
§ Introduction 
The immune system is vital in protecting the body against 
infectious disease and cancers. Toll-like receptor (TLR) 
activation is the first step in stimulating the immune system to 
respond to disease.1 As a consequence, TLRs are the target of 
several therapeutics, including vaccines2, cancer 
immunotherapies3, and autoimmune disease treatments.4,5 
Activators of TLR signaling, TLR agonists, are powerful 
immunostimulants due to their ability to drive innate and 
acquired immunity and are therefore sought after as adjuvants 
in vaccines.6 However, because they elicit strong immune 
reactions, administration of TLR agonists can have toxic side-
effects in vivo.7–9  
To mitigate these adverse effects, TLR agonists can be 
covalently conjugated to an antigen. This ensures simultaneous 
delivery of antigen and adjuvant to the same antigen presenting 
cell, which directs the response toward the antigen, thereby 
lowering the required dose for an effective immune 
response.10,11 These self-adjuvanting vaccines induce stronger 
humoral and cellular immune responses and are less toxic than 
vaccines comprised of co-administered antigen and adjuvant.10 
TLR agonists have also been conjugated to polymers12–14, solid 
particles15–17, or phospholipids18–20 to beneficially influence the 
compound’s drug properties. 
The benefits of TLR agonist conjugation can only be 
achieved if the conjugation does not perturb the interaction 
between the agonist and receptor. Therefore, effective strategies 
are required that facilitate TLR agonist conjugation with 
retention, or improved, TLR agonist potency. Here, we provide 
a review of the chemical requirements for successful TLR 
agonist conjugation strategies that have been employed, provide 
suggestions for alternative ligation strategies for existing TLR 
agonists, and insight for agonists that have yet to be conjugated.  
 
§ TLRs – Nomenclature and Function 
Toll-like receptors are a class of transmembrane pattern 
recognition receptors (PRRs). Their role is to recognize 
conserved molecular components of pathogens called 
“pathogen-associated molecular patterns” (PAMPs) as well as 
cellular damage-associated molecular patterns (DAMPs).21 The 
receptors are predominantly expressed in immune cells and 
show distinct expression patterns across different cell types.22  
The human TLR family comprises 10 functional TLRs that 
are expressed both on the cell surface (TLR1, 2, 4, 5 and 6) and 
intracellularly in endosomal compartments (TLR 3, 4, 7, 8 and 
9).23,24 The cellular localization of TLRs reflects the origin of 
the ligand it is responsible for detecting (Fig. 1). TLRs found at 
the cell surface respond to extracellular components of 
pathogens, including lipoproteins (TLR1, 2 and 6), 
lipopolysaccharides (TLR4), and bacterial flagellin (TLR5). 
Endosomal TLRs recognize components from the intracellular 
compartments of pathogens, such as double-stranded RNA 
(dsRNA, TLR3), single-stranded RNA (ssRNA, TLR7 and 8) 
and unmethylated cytosine-phosphate-guanine (CpG) DNA 
(TLR9).25 Although the role and natural ligand for human 
TLR10 is not yet fully understood, it is thought to be a negative 
regulator of TLR signaling.26–28 Binding of ligands to TLRs 
induces homo- or hetero-dimerization of TLR receptors and 
subsequent downstream signaling through two distinct 
pathways, the MyD88-dependent (TLRs 1, 2 and 4-9) and
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TRIF-dependent pathway (TLR3 and 4), generally mediating 
inflammatory and anti-viral responses respectively.29,30  
TLRs are crucial for their role in the innate immune system 
in fighting infection. They are responsible for the initial 
response to pathogens and their activity drives the generation of 
innate and adaptive immune responses. Innate immunity begins 
with the recognition of PAMPs through TLRs by antigen 
presenting cells (APCs), mainly dendritic cells (DCs) in the 
peripheral tissues.23 Binding of TLR ligands on dendritic cells 
initiates a downstream signaling cascade that initiates DC 
maturation. This process is characterized by the production of 
proinflammatory cytokines (TNF-α, IL-6 and IL-12), up-
regulation of costimulatory molecules (CD40, CD80 and 
CD86), increased antigen-presenting capacity, and DC 
migration from the peripheral tissues to draining lymph nodes.23 
There, antigen presenting DCs stimulate naïve T-cells which 
begins the adaptive immune response. B-cells also express 
TLRs and present antigen upon activation, resulting in antibody 
production specific for the encountered antigen. Since T- and 
B-cell maturation is influenced by TLR, costimulatory, and 
cytokine signaling, TLR agonists play an important role in 
establishing the type of cellular and humoral immune response 
that is generated. 
 
 
§ TLR Agonist Conjugates 
Due to their pivotal role in both the innate and adaptive 
immune system, agonists for TLRs have emerged as therapeutic 
agents, including as adjuvants in vaccines. Adjuvants function 
by activating immune cells exposed to antigen. Thus, the 
characteristics of efficacious adjuvants follow different design 
principles than traditional drugs. As reviewed by Wu31, an 
effective adjuvant should have a higher retention time at the site 
of administration to promote local immune system stimulation 
and prevent potentially harmful, off-target inflammation.  
In their review, Xu and Moyle32 state that direct conjugation 
of TLR agonists to antigen fulfills these requirements by 
ensuring co-delivery of antigen and adjuvant to immune cells. 
This enhances the generation of antigen-specific immune 
responses and prevents wasted inflammation.33 In addition, 
TLR agonists-conjugates have been used as chemical tools to 
study the role of TLR signaling in immune responses, which 
was recently reviewed by Oosenbrug and coworkers34. 
However, conjugation of TLR to antigens or other molecules 
requires thoughtful consideration in choice of TLR agonist, 
chemical linkage strategy, and site of conjugation. Here, we 
review conjugation of TLR agonists from a chemistry 
perspective to provide insight for future applications. 
 
 
 
Figure 1. Cellular location of TLRs, their ligands, and signal transduction pathways. TLRs 1, 2, 6, 4 and 5 are located on the plasma 
membrane and signal, together with endosomal TLRs 7, 8, and 9, in a MyD88-dependent manner. The MyD88 pathway leads to NF-κB 
translocation to the nucleus and, ultimately, production of inflammatory cytokines. Activated TLR4 is endocytosed and, together with 
endosomal TLR3, signals through the IRF pathway, leading to Type I interferon production. MD2, TRAM and TIRAP are adaptor 
proteins. 
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§ Conjugation strategies 
 
Ø TLR2  
The TLR2 subfamily is unique amongst TLRs in that it forms 
heterodimers with either TLR1 or TLR6 instead of homodimers 
(Fig. 2A). TLR2 is involved in the recognition PAMPs from a 
wide range of pathogens, including bacteria, viruses and 
fungi.35 The prototypical agonists to TLR2, however, are a class 
of bacterial di- or tri-acylated lipoproteins and lipopeptides and 
their synthetic analogues with N-terminal di- or tri-
palmitoylated cysteine residues (Pam2Cys, Pam3Cys 
respectively) (Fig. 2B). Pam2Cys and Pam3Cys bind TLR2 via 
two ester bound palmitoyl chains, whereas N-terminal acylation 
determines TLR1 or TLR6 specificity; an N-terminal fatty acid 
recruits TLR1 and a free N-terminal  amine recruits TLR6 (Fig. 
2A).36 They often contain the peptide-motif SK4, which 
enhances the agonists’ adjuvanticity and water-solubility.37 
Isomerically pure R-epimers of Pam2CSK4 (EC50: <1 nM) and 
Pam3CSK4 (EC50: 5 nM) are more potent TLR2 agonists than 
their racemic mixtures (EC50: 1nM and 20nM respectively), due 
to lower activity of the S-epimers.38,39 Because of their ability 
to induce robust maturation of DCs and effective humoral and 
cellular responses.40, these lipopeptides have been employed as 
adjuvants in many vaccine studies, even predating the discovery 
of TLRs.41     
Pam2Cys and Pam3Cys and their derivatives are the TLR2 
agonists most often found in bioconjugates due to their well-
defined chemical structure, ease of production, and the absence 
of natural endotoxins (Table 1). One exception is the TLR2-
TLR6 ligand, lipoteichoic acid (LTA), a major component of 
the gram-positive bacterial cell wall.42 LTA was conjugated to 
both CpG oligodeoxynucleotides (ODN) 182643,44, a TLR 9 
agonist, and to the cell surface of Lewis Lung Carcinoma (LLC) 
cells45 via a poly-ethylene glycol (PEG) linker. In both 
instances, conjugation of LTA was achieved by amide bond 
formation of the primary amines of side-chain D-alanines with 
N-hydroxysuccinimide (NHS) esters on heterobifunctional 
linkers. Despite its high potency, LTA has not been used in 
bioconjugation as extensively as Pam2Cys and Pam3Cys as 
endotoxin free LTA is difficult to produce and is therefore 
expensive. Moreover, the aforementioned conjugation 
strategies for LTA yield a mixture of high molecular weight, 
structurally diverse LTA-conjugates. Conversely, Pam2Cys and 
Pam3Cys are synthetically accessible and their conjugates can 
be made structurally homogenous. 
Triacylated TLR2-TLR1 agonists Pam3Cys and Pam3CSK4 
have been used extensively as conjugates to create self-
adjuvanting vaccines. For instance, Pam3Cys on the N-terminus 
of N. meningitidis lipoproteins greatly enhances the humoral 
response to Trumenba, an FDA approved, self-adjuvanting N. 
meningitidis vaccine.46,47 Pam3Cys and its derivatives are 
readily synthesized, structurally well-defined, commercially 
available, and do not suffer from the drawbacks associated with 
LTA. Conjugation with these compounds mainly proceeds 
through the C-terminal carboxyl group to avoid perturbation of 
N-terminal lipid interactions with the receptors (Fig. 2B). The 
incorporation of Pam3Cys and Pam3CSK4 into peptide-based 
vaccines can easily be achieved through standard solid-phase 
peptide synthesis (SPPS), placing Pam3Cys at the N-terminus 
of the peptide. Jung and coworkers were the first to apply this 
strategy for the synthesis of a peptide-based antigen-adjuvant 
conjugate.41 Conjugation of Pam3Cys to peptide antigens 
greatly increases antigen uptake, processing, and presentation48
  
and leads to enhanced humoral41,49 and cellular50 immune 
responses. Zeng et al.51 explored how the positioning of 
Pam3Cys in a peptide-conjugate affects the conjugates 
pharmacodynamic and immunogenic properties. Placing 
Pam3Cys in the middle of the peptide sequence dramatically 
increased the conjugates solubility and its ability to induce 
epitope-specific antibodies compared to terminally conjugated 
Pam3Cys, Similar results were obtained for TLR2-TLR6 
agonist Pam2Cys51, providing a powerful alternative to linear 
conjugation of lipopeptide TLR2 agonists.  
Preparation of glyco(lipo)peptide conjugates of Pam3Cys via 
SPPS has proven difficult. Issues with separation of the 
glyco(lipo)peptide conjugate after resin cleavage49 and lack of 
orthogonality between carbohydrate deprotection reagents and 
palmitoyl esters lead to alternative, convergent synthesis 
strategies. Several methods to create multi-component vaccines 
that contain the tumor-associated carbohydrate antigen (TACA) 
MUC1, a T-helper epitope, and Pam3Cys have been reported. 
The Boons lab has employed native chemical ligation 
(NCL)49,52 to sequentially conjugate TACA MUC1 to a T-
helper peptide epitope and Pam3CSK4. Other approaches 
involve functionalization of the C-terminus of Pam3Cys with a 
functional handle, such as alkynes53,54, a bromo- or iodoacetyl 
group55,  or a pentafluorphenyl-activated ester56,57, followed by 
conjugation to peptides and glycopeptide. Together, these 
Figure 2. TLR2 agonists bind dimers of either TLR2-TLR1 or 
TLR2-TLR6. (A) Crystal structure of human TLR2-TLR1-
Pam3CSK4 (PDB: 2Z7X). Red rectangle represents area of 
zoomed view of Pam3CSK4 binding to TLR2-TLR1. The 
analogous view from the TLR2-TLR6-Pam2CSK4 crystal 
structure is also shown (PDB: 5IJC). In both cases, the peptide 
C-terminus is solvent exposed. TLR2 shown in blue, TLR1 and 
TLR6 in orange, lipopeptides in green. TLRs in zoom view are 
shown at 40% transparency. (B) Chemical structure of 
Pam2CSK4 and Pam3CSK4. Green arrows highlight sites of 
conjugation. 
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examples show that Pam3Cys retains its potency in conjugates 
and that its conjugation is relatively straightforward in peptide-
based conjugates, but more demanding in glycopeptide 
conjugates.  
Conjugates of Pam3Cys can suffer from poor solubility in 
aqueous solutions and can therefore be difficult to dose and 
formulate in vaccines51. Pam2Cys, a synthetic analogue of the 
N-terminal lipopeptide motif of MALP-2, has a free amino 
group in place of the N-terminal palmitoyl chain in Pam3Cys 
resulting in improved solubility characteristics and increased 
potency towards splenocytes58 and macrophages59. The free 
amino group of Pam2Cys has also been used as a conjugation 
handle. After introducing a PEG spacer at the N-terminus, 
Vagner and coworkers conjugated relatively bulky 
functionalities, such as a chelating agent and fluorescent dyes,  
the N-terminal amine of Pam2Cys while retaining relatively 
high TLR2-TLR6 potency.60 In contrast, conjugation of 
photocage 2-(2-nitrophenyl)propyl chloroformate to the N-
terminal primary amine without a spacer dramatically decreases 
the activity of Pam2CSK4.61 These results suggest that the N-
terminus of Pam2Cys can be used for conjugation, but that a 
chemical spacer may be necessary to retain potency towards 
TLR2-TLR6. Similar to Pam3Cys, conjugation of Pam2Cys can 
also be accomplished by C-terminal conjugation, as was done 
in a conjugate of MALP-2 and MUC-162.  
Table 1. Overview of TLR1, 2, 3, 4, 5, and 6 agonist conjugates 
TLR Agonist Conjugation site Conjugation chemistry Conjugated to Ref.a 
TLR1/2 Pam3Cys C-terminus cysteine SPPS, NCL, CuAAC  Peptide, 
glycopeptide 
[132,166]; 
[49,52]; 54  
 Pam3CSK4 C-terminus lysine SPPS, thioether bond Peptide, 
glycopeptide 
[39,48,50]; 
55 
  ε-NH2 group lysine 
SKKKK 
CuAAC  Glycopeptide 
antigen 
167 
 Amplivant C-terminus lysine SPPS Peptide 64 
TLR2b Lipoamino acids N- and C-terminus SPPS Peptide and 
glycopeptide 
antigens 
69,132,168–
170 
TLR3 Poly(I:C) NH2 of any cytosine  Bisulfite catalysed 
transamination 
Polysaccharide 78 
  5’ termini Phosphoramidate coupling Nanoparticles 82,83 
TLR4 MPLA Reducing end 
anomeric centre 
Amide, CuAAC  Oligosaccharide [98–
100,102]; 
[101,171,172] 
  Non-reducing end 6’ 
position 
CuAAC  Oligosaccharide 101 
  Any free -OH group Carbamate  Protein 97 
 Pyrimido-indole Carboxamide group Amide  Polymer, TLR7/8- 
and 9 agonists 
13,43,107 
TLR5 Flagellin N- or C-terminus, or 
D3 domain 
Fusion proteins Various proteins Review32 
TLR2/6 Pam2Cys C-terminus SPPS, amide, CuAAC  Polymers, 
peptide, 
glycopeptide, 
TLR7- and NOD2 
agonists  
[49,132]; 
173–176]; 
177 
  N-terminus cysteine  Amide  Fluorophore, 
chelating agent 
60 
 MALP-2 C-terminus Amide  Glycopeptide  62 
 Pam2CSK4 C-terminus lysine Amide, SPPS  TLR7 and 9 
agonists 
[44,173]; 178 
  ε-NH2 of lysine 
SKKKK 
Amide  TLR7 agonist 173 
  N-terminus cysteine Thiourea, carbamate bond Fluorophore, 
photocage 
178; 108 
 LTA NH2 of any D-alanine Amide  LLC cells, TLR9 
agonist 
45; 44 
a References are clustered and ordered by conjugation chemistry. 
b TLR2 ligands for which the co-receptor is unknown. 
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Many structure-activity relationship (SAR) studies into 
Pam2Cys and Pam3Cys have been performed in order to 
optimize their adjuvant properties. These studies have resulted 
in several TLR2 agonist analogues with interesting chemical 
and immunological properties, but some of these have not yet 
been used in bioconjugates. By replacing the N-terminal 
palmitoyl amide-linkage of Pam3Cys for a urea-linkage, 
Willems and coworkers synthesized a Pam3Cys analogue called 
Upam (trademarked by Isa pharmaceuticals as Amplivant) that 
was shown to be a stronger inducer of DC maturation than 
Pam3Cys.63 Analogous to Pam3Cys, Amplivant was C-
terminally conjugated to a human papillomavirus (HPV) 
synthetic long peptide (SLP) vaccine and enhanced HPV 
antigen-specific cellular immune responses in ex vivo 
stimulated cervical tumour material.64 Similarly, Wu et al. have 
synthesized a Pam3Cys analogue with amide-linked palmitoyl 
chains (SUP3) and showed it was a superior adjuvant in an in 
vivo tumour challenge model.65  Both of these Pam3Cys 
analogues benefit from resistance to esterases, which is 
hypothesized to contribute to their adjuvanticity.65 Although 
SUP3 has not been used in antigen-conjugates so far it could be 
an excellent adjuvant for use in self-adjuvanting vaccines and 
perhaps even superior to Pam3Cys. Alternatively, Salunke et al. 
have reported on potent mono-palmitoylated lipopeptide 
analogues specific to human TLR2.66 These analogues are 
simpler in structure and synthetically more accessible than 
Pam3Cys, but have not been in conjugates as of yet despite their 
attractive properties. We suggest that any conjugation should 
proceed through the C-terminus, analogous to conjugations of 
Pam2Cys and Pam3Cys.   
An important consideration for the conjugation of lipopeptide 
TLR2 agonists are the biophysical effects accompanying the 
hydrophobic lipid chains. PamCSK4, Pam2CSK4 and Pam3CSK4 
can self-assemble into micelles in aqueous solution.67 These 
self-assembly characteristics have been exploited in self-
adjuvanting vaccines where lipopeptides are used as both 
adjuvant and delivery vehicle. Moyle et al. created multiple 
group A streptococcus (GAS) vaccines that contained either 
Pam2Cys, Pam3Cys or lipoamino acids, lipidated α-amino acids 
that are believed to activate TLR2.68,69 These compounds self-
assembled into nanoparticles of a suitable size (20-200 nm) for 
passive transport to the draining lymph nodes, which enhanced 
production of antigen-specific IgG antibodies in vivo68,69. 
Moreover, micellar self-assembly of TLR2 activating 
lipoproteins in N. Meningitidis vaccine Trumenba is thought to 
increase the stability of the lipoprotein antigens46]. However, 
the self-assembling nature of lipopeptide TLR2 agonists can 
differ between bioconjugates of different chemical 
composition. Thus, the biophysical characteristics of a specific 
lipopeptide-conjugate should be considered as these 
interactions may affect function.  
An alternative to lipopeptide TLR2 agonists are a group of 
non-lipid TLR2-TLR1 agonists, which were discovered by 
Guan et al. using high-throughput screening of a chemical 
library.70 Structurally distinct from lipopeptide agonists, these 
synthetically accessible small molecules display selective 
potency towards TLR2-TLR1 at concentrations as low as 30 
nM, with some of them being selective for either human or 
mouse TLR1-TLR2. The small molecules have not yet been 
used in bioconjugates, nor is there any information available on 
SAR or binding characteristics. Thus conjugation with these 
agonists would be more exploratory. However, due to their 
small molecule nature, these TLR2-TLR1 agonists could find 
use in conjugate applications in which lipopeptide bulk or 
hydrophobicity would be problematic.  
Both large and small molecule agonists have been described 
for TLR2. In considering a conjugation strategy, the 
palmitoylated peptide family offers appealing aspects of 
processability with the C-terminus providing a viable target for 
most bioconjugation methods. However, biophysical 
aggregation must be considered. Future work might explore 
novel ligands containing more simple, hydrophilic chemical 
motifs to improve accessibility and enhance solubility while 
avoiding systemic immune activation. 
 
Ø TLR3 
TLR3 is an endosomal TLR that senses the negatively 
charged backbone of double-stranded RNA (dsRNA) that is an 
intermediate in the replication of ssRNA viruses and makes up 
the genome of some dsRNA viruses  (Fig. 3A).71 This receptor 
is unique among TLRs as it signals solely through the TRIF 
pathway. The commonly used TLR3 agonist is a high molecular 
weight synthetic dsRNA analogue, polyinosinic-polycytidylic 
acid (poly(I:C)).72 Poly(I:C) is a potent stimulator of 
conventional DCs (cDCs) and effector T-cell responses.73 
However, its development as a vaccine adjuvant has been 
hampered by its in vivo toxicity at high doses9, which have been 
partially attributed to additional signaling through cytosolic 
PRRs MDA-5 and RIG-1 in addition to TLR3.74 These effects 
could potentially be mitigated by poly(I:C) conjugation with 
other compounds. Alternative dsRNA TLR3 agonists IPH-
310275, Rintatolimod76 (poly-IC12U) and poly-ICLC77 show 
reduced toxicity but have not been used as TLR-conjugates as 
of yet.  
 Despite the clinical potential for TLR3 agonist conjugates, 
few examples exist of poly(I:C)-conjugates (Table 1). Huang et 
al. conjugated commercially available poly(I:C) to a protein 
antigen by introducing linkers on the cytosine primary amines 
using sodium bisulfite catalyzed transamination reactions.78 
This strategy invariably leads to a heterogeneous mixture of 
conjugates however, as there are multiple cytosines within a 
poly(I:C) molecule. Although they have not been directly 
compared in a study, we speculate, that conjugation on the 
nucleobases of poly(I:C) is more likely to disrupt binding to 
TLR3 than conjugation to the termini, due to the fact that 
dsRNA binding to TLR3 requires a stretch of at least 40-50 
unobstructed base pairs (Fig. 3A).79  To conjugate poly(I:C) 
with its termini, one can employ phosphoramidate chemistry on 
terminal 5’-phosphates (Fig. 3B).80,81 This technique was used 
by Shukoor et al. to conjugation poly(I:C) to g-Fe2O3 
nanoparticles with its 5’ terminal phosphates82,83. 
Zhang et al. recently reported84 on the only known class of 
small molecule TLR3 agonists. Their lead compound, CU-
CPT17e, is a weakly potent human TLR3 agonist (EC50: 4.8 
µM) and can also signal through human TLRs 8 (EC50: 13.5 
µM) and human TLR9 (EC50: 5.7 µM), while signaling through 
murine TLRs was not investigated in this study. CU-CPT17e 
and its analogues could be a useful alternative to poly(I:C) in 
conjugates that require small molecule TLR3 agonists. 
However, SAR studies show that alterations to the structure of 
CU-CPT17e consistently leads to abrogation of TLR3 
potency84, complicating the successful conjugation of this small 
molecule TLR3 agonist. Alternatively, studies have shown that 
nucleic acid based adjuvants can be associated with various 
molecules, including antigens, through electrostatic interactions 
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with the backbone phosphates. Zhang et al. demonstrated this 
technique to form polyelectrolyte multilayer vaccines 
composed of poly(I:C) and cationic ovalbumin (OVA) peptide 
antigens which stimulated robust T cell responses.85 Follow up 
studies further characterized these materials and their ability to 
generate powerful immune responses.86,87 
In conclusion, TLR3 has a unique signaling pathway and 
immunological activity but has been limited in application due 
to a lack of agonists. Although highly potent, commercially 
available dsRNA TLR3 agonists are bulky, polydisperse and 
difficult to characterize using conventional chemical analysis 
techniques. Conjugation of prototypical TLR3 agonist 
poly(I:C) can proceed by introducing chemical handles to 
cytosines along its backbone. However, we suggest that the 
terminal ends of dsRNA analogues may be better sites for 
conjugation based on site availability as suggested by crystal 
structure analysis and the homogenous nature of such a 
compound. The recently reported class of small molecule TLR3 
agonists are attractive due to their small molecule nature, but 
they are considerably less potent towards TLR3 than poly(I:C). 
Thus, the field would benefit from the discovery of novel, 
potent small-molecule ligands that are exclusive agonists of 
TLR3 and can be modified to generate bioconjugates. 
 
Ø TLR4 
TLR4 was the first human TLR identified to bind a ligand, by 
Poltorak et al.88 and Hoshino et al.89, and is the most studied 
among the TLR family. TLR4 binds ligands with the aid of 
myeloid differentiation factor 2 (MD2), forming a TLR4-MD2-
agonist complex (Fig. 4A).90 TLR4 is unique among TLRs in 
that upon ligand binding, it can signal through both the MyD88 
and TRIF pathways (Fig. 1), resulting in a variety of accessible 
immune response profiles.91 Some TLR4 agonists bias 
particular signaling pathways, presumably through differing 
conformational changes and cellular location upon receptor 
binding, resulting in unique immune responses.92 Thus, tuning 
the chemical structure of these agonists impacts the 
immunological activity of the compound. Its main natural 
binding ligands are lipopolysaccharides (LPS), major 
components of the Gram-negative bacteria cell membrane 
responsible for bacterial sepsis (Fig. 4A).90 Although many 
forms of LPS exist, the toxicity of these molecules has 
prevented their use in vaccines. However, several groups, 
notably Qureshi et al.93, developed a detoxified analog of LPS, 
monophosphoryl lipid A (MPLA), which is now FDA approved 
as an adjuvant in multiple vaccines and is currently in several 
clinical trials.94 The diversity in chemical composition and 
immunological activity of TLR4 agonists presents opportunity 
for chemical manipulation in a variety of TLR conjugate 
applications (Table 1). 
The glycolipid moiety in LPS-derived TLR4 agonists 
contains several sites for modification. MPLA was the first 
example of an intentionally modified LPS derivative and has 
since been used heavily as a vaccine adjuvant. MPLA is the 
lipid A component of LPS, but lacking the reducing end 
phosphate, which decreases the toxicity over 1000-fold (Fig. 
4B).95 The reduction in toxicity has been attributed to the bias 
of activation toward the TRIF pathway over MyD88 pathway, 
resulting in less pro-inflammatory cytokine production.96 
Modifications that bias activity have been further exploited to 
tune the immunomodulatory properties of the agonist. For 
example, Carter and coworkers have described glucopyranosyl 
lipid adjuvant (GLA) and second-generation lipid adjuvant 
(SLA), MPLA analogues with varying lipid chain lengths that 
elicit distinct immunological responses and activate both mouse 
and human TLR4.92 Although these modifications can be used 
to tune the immune response, they are not sites amenable to 
conjugation chemistry as this portion of the molecule directly 
binds to the MD2-TLR4 complex (Fig. 4B).  
Although the hydrophobic portions of glycolipid TLR4 
agonists are not ideal sites of conjugation, the exposed 
functional groups of the sugars have been used as conjugation 
handles. In one example, Schülke et al reacted MPLA with 
carbonyldiimidazole (CDI) followed by OVA to form a non-
specific MPLA-OVA conjugate.97 The conjugation resulted in 
boosted immune responses toward OVA compared to the 
mixture of unconjugated MPLA and OVA. In another example, 
  
Figure 3. TLR3 agonists are dsRNAs that bind to TLR3 
dimers. (A) Crystal structure of mouse TLR3-dsRNA (PDB: 
3CIY). The receptors bind to the negatively charged backbone 
of the dsRNA molecule. TLR3 shown in blue and orange, 
dsRNA shown in green. (B) Carton structure of dsRNA with 
sites that have been conjugated highlighted by green arrows 
and suggested sites of conjugation by blue arrows. 
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Guo and coworkers developed a synthetic strategy to afford an 
MPLA derivative with an amino linker appended to the non-
reducing hydroxyl group.98–100 Conjugates of this derivative 
with TACAs via amide bond formation afforded self-
adjuvanting, glycoconjugate cancer vaccines. Recently, Wang 
et al. did a SAR study on MPLA conjugation to a 
lipoarabinomannam oligosaccharide and found that non-
reducing 6’—hydroxyl conjugates had superior immunological 
activity to 1-O-conjugates.101 The Guo lab also used 6’-
hydroxyl conjugation of MPLA to produce an MPLA-Group C 
Meningitis glyco-antigen-conjugate vaccine.102 Although the 
synthetic method developed in this study resulted in 10-100’s 
of mg of MPLA derivatives amenable to a variety of 
conjugation strategies, the approach requires expertise in 
synthetic organic carbohydrate chemistry, which may not be 
present in many vaccine development teams. If covalent 
conjugation is not an option, non-covalent co-delivery 
strategies for MPLA and antigen could be considered. Several 
 
Figure 4. TLR4 agonists bind MD2 and TLR4. (A) Crystal structure of human TLR4-MD2-LPS (PDB: 3FXI) from two viewpoints 
(left), red rectangle depicts zoom view of LPS binding (middle) in which proteins are shown with 40% transparency. The analogous 
view from the mouse TLR4-MD2-Neoseptin-3 crystal structure is also shown (PDB: 5IJC, right). TLR4 shown in blue and orange, MD2 
shown in gray, LPS and Neoseptin-3 shown in green. (B) Chemical structures of various TLR4 agonists. Areas that bind MD2 (dotted 
gray) and TLR4 (dotted orange) shown. Green arrows highlight previous sites of conjugation, blue arrows highlight suggested sites of 
conjugation. 
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studies have reported enhanced adjuvant effects when 
incorporating glycolipid TLR4 agonists into emulsions, 
including some FDA approved vaccines, a straightforward 
strategy given the hydrophobicity of the compounds.103–105 
Thus, small molecules may be more advantageous for 
applications involving direct chemical linkage for the greater 
ease in chemical manipulation and hydrophilicity. 
Recently, a variety of small molecule TLR4 agonists bearing 
little structural resemblance to glycolipids have been 
developed. These include pyramido-[5,4-b]indoles, 4-
aminoazoquinolines, α-aminoacyl amide “Ugi products,” and 
neoseptins. Given their synthetically accessible nature, these 
molecules are more amenable to functionalization for various 
applications. However, all of these molecules bind 
predominantly within the MD2 pocket, making it difficult to 
introduce chemical modifications without sacrificing agonist 
potency (Fig. 4B). Therefore, it is critical to evaluate the site of 
modification before embarking on a synthetic route to obtain 
the desired conjugate. 
The pyramido-[5,4-b]indoles were discovered by Chan and 
coworkers via high throughput screening in 2013.106 The hit 
compound in this study (Compound 28, EC50: 1-10 µM) was 
shown to stimulate high production of IP-10/CXCL10 and IL-6 
in vitro. Variations of this molecule have been used in 
conjugation studies, including multi-valent TLR conjugates, by 
introducing a linker on the carboxamide moiety.43,107 In another 
study, Lynn and coworkers synthesized a derivative of the lead 
pyramido-[5,4-b]indole compound by adding an amine 
functionality to a carboxamide cyclohexyl group, which was 
then conjugated to N-isopropylacrylamide (NIPAM) polymers 
using a bivalent tetraethylene glycol linker.13 In addition, the 
indole nitrogen has been functionalized with 
nitroveratryloxycarbonyl (NVOC) to afford a light-activated 
TLR4 agonist, showing that this site is important for ligand 
binding despite docking studies suggesting it may be solvent 
accessible.108 More recently, a further optimized pyramido-
[5,4-b]indole TLR4 agonist (Compound 26, EC50: 600 nM, Fig. 
4B) was shown to improve and bias human TLR4 activation 
over mouse TLR4 activation.109 Although this molecule has yet 
to be implemented in conjugation applications, we expect it to 
behave similarly to the original hit molecule, Compound 28, 
based on reported docking studies and SAR studies. 
The same group discovered substituted 4-aminoquinazoline 
human TLR4 agonists by high throughput screening in 2014.110 
The hit compound (Compound 1a, EC50: 2 µM) was predicted 
to bind in a similar manner as pyramido-[5,4-b]indole 
compounds in docking studies, despite the lack of structural 
similarity. SAR studies suggested that the ester moiety may be 
amenable to derivatization for conjugation applications as 
functionalization with bulky groups had favorable effects on 
potency (Fig. 4B). However, docking studies suggested that this 
site may reside at the interface of TLR4 and MD-2, meaning 
that conjugation to this site may require a linker to prevent 
perturbation of TLR4-MD-2 dimerization. 
Neoseptin-3 is a peptidomimetic molecule discovered by 
Wang et al. through screening compounds for activation of 
TLR4-MD2 in murine macrophages.111 Despite the simple 
design, the molecule has few sites amenable to chemical 
functionalization due to the unique binding mechanism of the 
compound. Two Neoseptin-3 molecules bind asymmetrically 
within the same binding pocket of the TLR4-MD2 complex, a 
property which is thought to be unique among all studied 
protein-ligand interactions (Fig. 4A). The Neoseptin-3 aniline 
moiety appears to be a potential site of conjugation, based on 
the reported SAR study and crystal structure evaluation (Fig. 
4B). However, while one of the molecule’s aniline appears to 
be solvent exposed, the other interacts with TLR4 residues. 
Hypothetically, stimulation with a 1:1 mixture of conjugated 
and unconjugated Neoseptin-3 molecules may avoid this issue. 
However, this strategy may result in little Neoseptin-3-
conjugate binding if the conjugate affinity for the receptor is 
lower than unconjugated Neoseptin-3. Thus, Neoseptin-3 
conjugation strategies would likely require empirical design 
and testing to determine effective sites or linkers needed. In 
addition, Neoseptin-3 only activates mouse TLR4, limiting its 
practical use. 
Marshall et al. developed the human TLR4 stimulating “Ugi 
compounds” using a combinatorial molecule screen with Ugi 
multi-component reaction products.112 These molecules were 
highlighted for their high potency and hydrophilicity. One of 
the lead compounds in the study, AZ617 (Fig. 4B, EC50: 6.3 
nM), was within an order of magnitude of LPS potency (EC50: 
2.4 nM) and exhibited ideal hydrophilicity characteristics. 
Docking studies suggest that the compound binds in a similar 
location to other small molecule TLR4 agonists, between MD-
2 and TLR4. In this case, the free carboxyl group appears to be 
close to the solvent exposed area of the binding pocket. Thus, 
conjugation to other molecules, potentially through amide or 
ester bond formation, might be possible at this site. In fact, some 
derivatives in SAR studies contained an alkyne substituted for 
the carboxyl group, among other modifications, making it 
amenable to click chemistry. However, these compounds 
suffered a 10-100 fold drop in activity and reduced 
hydrophilicity compared to AZ617. 
Neve and coworkers demonstrated Euodenine A, a natural 
product isolated from Papua New Guinea Tree, derivatives had 
low µM affinity for human TLR4.113 SAR studies suggest that 
substituting the methyl group appended to the cyclobutyl 
moiety in Euodenine A with functional handles for conjugation 
may be tolerated. However, no docking studies are reported for 
this molecule, making conjugation attempts to the molecule 
more empirical relative to other small molecule TLR4 agonists. 
In summary, TLR4 agonists have great potential as 
immunological modulators as demonstrated by their clinical 
use. These applications could be expanded or improved with 
TLR4 agonist conjugates. Although most applications have 
used glycolipid based TLR4 agonists, like MPLA or GLA, 
these compounds are difficult to conjugate effectively. 
Alternatively, several small molecule TLR4 agonists exist with 
a range of chemical structure and potency. However, SAR 
studies have demonstrated that potency is sensitive to small 
changes in chemical structure. Thus, TLR4 agonist conjugation 
strategies could be advanced by developing simplified 
glycolipid synthesis protocols, reliable modification 
techniques, and by improved design of small molecules 
amenable to conjugation. Billod et al. recently reviewed 
computation based approaches for TLR4 ligand prediction and 
design, which could aid in the development of TLR4 agonists 
for conjugation.114 
 
Ø TLR5 
TLR5 resides on the cell membrane and responds to 
flagellin.115,116 Flagellin is a bacterial protein (~50 kDa) that 
self-assembles to form the flagellum organelle, providing 
motility for the organism. Recombinant flagellin and modified 
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variants are also potent activators of TLR5.117–119 TLR5 agonist 
conjugates have largely been used as recombinant fusion 
proteins with disease related antigens to generate single 
molecule vaccines, several of which are in clinical trials (Table 
1).120–122 Recombinant expression of antigens with fused 
flagellin may not work in every application. For example, the 
fused protein may have poor solubility characteristics, 
compromise antigen expression, block antibody epitopes, or 
generate immune responses that are not well suited for specific 
applications. To overcome some of the limitations of flagellin-
antigen fusion proteins, several studies have shown that co-
delivery of flagellin-coated nanoparticles and antigen can also 
be used as effective vaccines.123–125 Flagellin has also been 
conjugated to other compounds through non-site specific cross 
linking chemistries with surface exposed lysines.118,126–128 In 
these studies, authors have noted that the conjugation approach 
could be improved by generating flagellin variants which are 
designed to facilitate conjugation in portions of the protein that 
are not involved with TLR5 binding. 
The only synthetic small molecule agonists for TLR5 are 
flagellin derived peptides.129 These peptides share homology to 
flagellin’s highly conserved D1 binding domain and can be as 
small as 13 residues in size. To our knowledge, conjugates of 
flagellin derived peptides have yet to be synthesized for vaccine 
applications. The flagellin peptide should be amenable to 
conjugation with other peptides or molecules via traditional 
SPPS approaches. However, we observed no in vitro activity of 
TLR5 peptides or TLR5 peptides conjugated with small 
molecules in initial studies (unpublished data).  
 
Ø TLR7 and TLR8   
TLR7 and TLR8 agonists are among the most studied of the 
TLR family. Similar to TLR3 and TLR9, the receptors are 
located in the endosome and bind nucleic acid-based agonists 
(Fig. 5A).130 However, unlike TLR3 and 9, TLR7 and 8 are 
expressed across most human immune cell types. This feature 
has made TLR 7 and 8 targeting adjuvants sought after to 
generate efficacious T cell responses in human vaccines.131 In 
addition, most TLR7/8 agonists are effective across many 
species.   
The natural ligands for TLR7 and TLR8 are ssRNAs of viral 
origin.130 Due to the poor drug properties of RNA, several small 
molecule agonists have been developed, including 
imidazoquinolines, purine derivatives, and guanosine  
analogues.75 Many of these heteroaromatic molecules are 
agonists for both TLR7 and TLR8.132 However, empirical 
testing, crystal structure examination, and SAR studies have 
shed light on the structural requirements for TLR7 or TLR8 
agonist specificity.133–135 These small molecule agonists have 
been effectively utilized as immunostimulants in a variety of 
applications. One synthetic small molecule imidazoquinoline 
TLR7 agonist, Imiquimod, is approved for clinical use in 
topical treatment of certain skin cancers, genital warts, and skin 
conditions.136 However, promising results in vitro are often  
difficult to recapitulate, and even potentially toxic, in vivo.8,137 
This observation has been attributed to the molecules’ 
pharmacokinetic properties as they rapidly diffuse to the blood 
stream, resulting in systemic cytokine production and 
inflammation.31 Due the practical issues, yet clinical promise, 
of TLR7/8 agonists, they have received considerable attention 
as TLR conjugates (Table 2). The basic chemical structure of 
these heteroaromatics have multiple sites amenable for 
functionalization; both a primary and secondary amine are 
present for conjugation, as well as an aromatic ring system 
capable of bearing other functional groups. Several conjugation 
strategies have been successfully employed, but the potency 
and biological effects of the conjugates varies greatly. 
Most adenine analogues found in conjugate applications are 
tethered through a substituted N1-benzyl linker, based on the 
potent TLR7 agonist 9-benzyl-8-hydroxy-2-(2-methoxyethoxy) 
adenine (SM360320).138 Wu and coworkers were the first to 
synthesize a SM360320 derivative for conjugation by 
functionalizing the N1-benzyl with an aldehyde moiety.139 The 
resulting TLR7 agonist, UC-1V150 (Fig. 5B), was ligated to 
hydrazine functionalized mouse serum albumin (MSA), while 
retaining its TLR7 agonist activity. Another conjugation 
method, from the same lab, involved using an N1-benzylic 
carboxylic acid UC-1V150 analogue, which was conjugated to 
phospholipids, with or without PEG spacers.18 Adenine 
derivatives have also been ligated through N1-alkyl linkages,  
 
Figure 5. TLR7/8 agonists bind TLR7 and/or TLR8 
homodimers. (A) Crystal structure of monkey TLR7-
Resiquimod (PDB: 3FXI), red rectangle depicts view of 
Resiquimod binding (right) in which proteins are shown at 20% 
transparency. The molecule bridges the receptors at the 
interface. TLR7 shown in blue and orange, Resiquimod shown 
in green. (B) Chemical structures of various TLR7/8 agonists. 
Green arrows highlight recommended sites of conjugation. 
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although this resulted in less potent conjugates. Alternatively, 
Weterings and colleagues have described a method to 
covalently link a 2-alkoxy-8-hydroxyadenine derivative 
through an ethylene glycol linked azide on its C-2 position to 
OVA peptide epitopes.140 This adenine derivative was 
conjugated to a peptide epitope through click chemistry, 
creating a self-adjuvanting vaccine. Although conjugation of 
the TLR7 agonist increased presentation of the antigen, it also 
abolished the induction of DC activation. The authors suggest 
steric hindrance of the peptide moiety may influence binding of 
the conjugate to the TLR.  
Similar to adenine analogues, conjugation of 
imidazoquinolines mainly proceeds through benzylic linkages. 
Shulka and coworkers conjugated an N1-(4-
aminomethyl)benzyl substituted imidazoquinoline (analogue 
5d, Fig. 5B) to three fluorescent dyes, fluorescein, rhodamine 
B, and BODIPY-TR-cavarine, either directly or by first 
converting the free amine to an isothiocyanate.141 In doing so, 
they created potent, fluorescent probes for TLR7 activation. 
The same group also ligated N1-(4-aminomethyl)benzyl 
substituted imidazoquinolines under more mild conditions. By 
converting the free amine to an isothiocyanate- and maleimide-
group, they conjugated the TLR agonist to both a model peptide 
and reduced glutathione, in aqueous buffer, without additional 
reagents.142 The amino group was also reacted directly with a 
model oligosaccharide under reductive amination conditions. 
All resulting conjugates were obtained in high yield and 
preserved their agonistic activity.  
Lynn et al. demonstrated ligation of N1-alkyl and N1-(4-
aminomethyl)benzyl substituted (analogue 5d reported 
previously) TLR 7 agonists.13, 143 They showed that the benzylic 
linker (Fig. 5B, EC50: 0.1 µM) increased potency of the 
conjugates 20-fold compared to the alkyl linker (EC50: 2 µM) 
inspired by previously reported SAR studies.144 The benzylic 
imidazoquinoline compound was conjugated to a N-(2-
hydroxypropyl)methacrylamide (HPMA) polymer which 
enhanced its immunological activity in vivo. This effect was 
achieved by causing accumulation in the draining lymph node 
instead of diffusion to the bloodstream. 
Conjugation of imidazoquinolines through the C-4 amine 
resulted in a complete loss of agonist activity according to SAR 
studies145 and crystal structures146 of TLR8. In one example, a 
method to gain spatial and temporal control over immune cell 
activation was demonstrated by photocaging the C-4 amine of 
Imiquimod and Resiquimod.147 The free C-4 amine of the 
imidazoquinolines was functionalized with 2-(2-
nitrophenyl)propyl chloroformate (NPPOC-Cl), creating a 
light-responsive TLR agonist. TLR7/8 agonist dimers linked 
Table 2. Overview of TLR 7, 8, and 9 agonist conjugates 
TLR Agonist Conjugation site Conjugation chemistry Conjugated to Ref.a 
TLR7 SM360320 N1-benzyl  linkage Amide, hydrazone  Polymer, protein, 
phospholipid 
14; [18,139] 
  N1-alkyl linkage Amide  Protein  179 
 2-alkoxy-8-
hydroxyadenyl 
derivative 
C-2 linkage CuAAC  Peptide 140 
TLR7/8 3M-012 N1 linkage thiol-maleimide, UV light 
induced coupling  
Peptide, protein  150; 149 
 Resiquimod C-4 linkage Carbamate linkage Photocage  147 
 N1-benzyl 
imidazoquinoline 
N1-benzyl linkage Thiourea, reductive 
amination, amide 
Flourophore, 
protein, TLR7/8 
agonist  
142; 141; 148 
  C-4, N1-benzyl, N1-
alkyl linkage  
Amide  Polymer 13 
 Imidazoquinoline 
amino acid 
N- and C-terminus SPPS Peptide  155 
 Loxoribine C5’ OH of ribose  CuAAC TLR4- and 9 
agonist 
 
TLR9 Class A CpG  5’ Phosphate Phosphoramidite Phospholipid 20 
 Class B CpG 5’ Phosphate Thioether, Thiol-
maleimide, 
phophoramidite, CuAAC, 
bis-aryl hydrazone, 
reductive amination, 
disulfide 
TLR4-, 7/8 and 9 
agonists, 
polymers, biotin, 
fluorophore 
phospholipid, 
protein   
163; 
[19,107,180]; 
20;  181; 165; 
12; 15 
 Class B CpG  3’ Phosphate Amide, thiol-maleimide, 
bis-aryl hydrazone  
LLC cells, 
TLR2/6- and 4 
agonists, peptide, 
protein 
45; [44,48]; 
165 
 Class C CpG   5’ Phosphate Disulfide coupling, 
phosphoramidite 
Nanoparticles, 
phospholipid 
15; 20 
a References are clustered and ordered by conjugation chemistry. 
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through their C-4 amine also display sharply decreased TLR7 
agonist activity compared to N1-benzyl linked dimers.148 
Willie-Reece and coworkers demonstrated the promise for 
TLR7/8 agonist-antigen conjugates as a subunit HIV vaccine.149 
An amine functionalized resiquimod (3M-012) was 
photocrosslinked with HIV Gag protein. The conjugate was 
shown to potently stimulate T and B cell responses, in mice and 
non-human primates, toward the antigen whereas the un-
conjugated mixture did not. A thiol-functionalized 3M-012 was 
also crosslinked via thiol-maleimide chemistry to HIV envelope 
protein.150 Despite high immunostimulatory activity, the 
conjugation blocked antibody responses toward certain antigen 
epitopes. Recently, the same lab demonstrated that protective T 
cell responses via TLR7/8-antigen conjugates required 
aggregation of the conjugate.151 In addition, Holbrook and 
coworkers conjugated an amine functionalized Resiquimod to 
influenza virus via a bifunctional NHS-maleimide peg linker.152 
This and follow up studies demonstrated the Resiquimod-
influenza conjugate vaccine generated efficacious influenza 
immunity in non-human primate neonates, a difficult 
vaccination model.153,154 These studies highlight both the 
clinical potential of TLR7/8 agonist conjugates and the need to 
development site-specific methods for agonist conjugation to 
improve antigen-specific immune responses while preserving 
antigen recognition. 
Further broadening the scope of conjugation strategies for 
TLR7/8 agonists, Fujita and coworkers synthesized an 
imidazoquinoline-like amino acid, 6-(4-amino-2-butyl-
imidazoquinolyl)-norleucine.155 Although weakly potent, the 
novel amino acid provides a way to easily introduce 
imidazoquinolines into peptides via SPPS. To create a more 
potent TLR7/8 agonistic amino acid we speculate that 
substituting norleucine for phenyl alanine to create 4-((4-
amino-2-butyl-imidazoquinolyl)methyl) phenylalanine, which 
contains the N1-benzyl substituent associated with high TLR7/8 
agonist activity. Such a highly potent imidazoquinoline-like 
amino acid would enable facile synthesis of powerful self-
adjuvanting vaccines targeting TLR7/8 through SPPS.  
Wu and coworkers have developed a guide to effectively 
modify imidazoquinoline-like TLR7/8 agonists to create small 
molecule immunopotentiators (SMIPs).33 They showed that 
creating an antigen depot effect was key for in vivo adjuvant 
effectiveness by limiting “wasted inflammation” and directing 
immune responses toward intended targets. This effect was 
achieved by making the molecules more lipophilic through 
conjugation with hydrophobic moieties. However, they found 
these conjugates were impractical due to scale- and formulation 
issues caused by poor conjugate solubility. Instead, the group 
found that by conjugating SMIPs to phosphate-functionalized 
PEG linkers followed by non-covalent absorption with alum, 
the depot effect was achieved to yielding effective adjuvants. 
Loxoribine is the only guanosine analogue to yet be 
conjugated. In an effort to synthesize a tri-valent TLR agonist 
conjugate, a Loxoribine derivative amenable to conjugation was 
synthesized by substituting the 5’ primary alcohol for an azide 
(Fig. 5B).107 The Loxoribine-azide was conjugated to an 
alkyne-functionalized core molecule through copper(I)-
catalyzed alkyne-azide cycloaddition (CuAAC). However, 
whether this conjugation strategy preserves TLR7/8 agonist 
potency remains uncertain. Conjugation of Loxoribine to a di-
agonist of CpG ODN (TLR9) and indole (TLR4) did not 
increase the conjugate’s potency, which we attribute to the 
relatively low potency of Loxoribine.  
In summary, TLR7/8 agonists are synthetically accessible, 
relatively potent, and highly amenable to conjugation. 
Conjugation of TLR7/8 agonists to phospholipids and polymers 
has proven to be an effective strategy in improving their 
pharmacodynamics/pharmacokinetic properties and their 
conjugation to protein- and peptide antigens creates highly 
immunogenic self-adjuvanting vaccines. In addition, the 
synthesis of TLR7/8 agonist conjugates is as the compounds are 
more amenable to synthetic methods than lipidated TLR4 
agonists. Together, these qualities make TLR7/8 agonists 
appealing immunostimulants for bioconjugation in many 
applications.    
 
Ø TLR9 
TLR9 is located in the endosome and senses DNA rich in 
unmethylated CpG dinucleotides. TLR9 also binds synthetic 
CpG oligodeoxynuceotides (ODNs), which are short, single-
stranded DNA (ssDNA) oligomers with unmethylated CpG 
motifs (Fig. 6A). CpG ODNs induce strong cellular and 
humoral responses against co-administered antigens, making 
them highly attractive vaccine adjuvants.156 The sequence of the 
CpG ODN dictates the species specificity of the agonist, with 
many commercially available varieties developed for human, 
murine, bovine and other organisms.  
CpG ODNs have been used in bioconjugates for a variety of 
applications; CpG ODNs have been conjugated to peptide 
antigens48, antibodies157, other TLR agonists43,44,107, 
nanoparticles15,158, cancer cells45 and lipids19,20 (Table 2). 
Conjugation of CpG ODNs to nanoparticles and lipids can 
improve pharmacokinetics, pharmacodynamics, and targeting 
of the adjuvant to draining lymph nodes.12,20 Conjugation of 
CpG ODNs to antigens can improve antigen uptake, antigen 
presentation48, and cross-priming159 of cytotoxic T-
lymphocytes. However, some have noted that promising results 
in animal models may not translate to humans, as TLR9 
expression across human immune cell types are more limited.160 
Exciting for the field, the first vaccine with unconjugated CpG 
(Heplisav) was just approved for use in humans indicating the 
vast potential of this class of compounds. 
Many studies report conjugates of CpG ODN linked through 
either the 3’ or 5’ end (Fig. 6B). However, the optimal 
orientation for CpG ODN in conjugates remains controversial. 
The crystal structure of extracellular domain of horse TLR9 
ligated to CpG suggests that the 5’ end may be more accessible 
for conjugation (Fig. 6B). It should be noted however that the 
5’ end is positioned at the bottom of the TLR9 complex, 
towards the endosomal membrane, which could inflict steric 
constraints on 5’ end CpG conjugates. Crystal structure analysis 
has been insufficient to determine optimal binding sites as 
suggest by SAR studies. Initial reports by Agrawal and co-
workers suggested that the 3’ end was ideal for conjugation and 
that a free 5’ end was essential for agonist potency.161 For 
example, CpG dimers that were conjugated 5’-to-5’ were 
significantly less immunogenic than 3’-to-3’ tethered CpG 
ODNs, measured by the in vitro induction of spleen lymphocyte 
proliferation and splenomegaly. 161 In a follow-up study, this 
decrease in TLR9 potency for 5’ conjugation was shown to be  
dependent on the size of the attached moiety and independent 
of cellular uptake.162 In vivo, 5’ conjugation of CpG ODNs to a 
bulky amyloid-β peptide antigen sharply decreased IL-12 
induction, while 3’ conjugates elicited strong IL-12 responses 
in C57BL/6 mice.163  
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However, some studies contradict the notion that 5’ 
conjugation of CpG ODNs leads to reduced TLR9 potency 
compared to 3’ conjugation. Zhang et al. showed that 5’ 
conjugation of class B CpG ODN 1826 to bulky dextran  
polymers did not alter NF-κB activity in TLR9-transfected 
HEK293 cells.12 It is however important to note that an acid 
labile imine bond164 was used to conjugate CpG to dextran in 
this study, which could facilitate release of CpG after 
endosomal uptake. Acid hydrolysis of the imine bond would 
free the 5’-end of CpG and allow unobstructed binding to 
TLR9, which would explain why CpG conjugated to dextran 
retained TLR9 potency. We have however also observed (2-
fold) decreased TLR9 activity upon 3’ CpG conjugation via 
thiol-maleimide chemistry with a triazine linker, while activity 
was maintained when conjugated through the 5’ end 
(unpublished data). In an effort to end the controversy, Kramer 
et al. recently compared conjugation of CpG ODN 1668 to an 
ovalbumin (OVA) protein antigen through both 3’ and 5’ ends 
using an acid-stable bis-aryl hydrazone linker (Solulink Inc.).165 
Interestingly, no statistically significant difference was found in 
the induction of proliferation of CD4+ and CD8+ T- cells and 
IFN-γ production in T-cells from OT-I and OT-II mice between 
the 3’ and 5’ CpG-OVA conjugates.165 This study suggests that 
both 3’ and 5’ conjugation of CpG ODNs yield conjugates with 
comparable potency for induction of cellular T-cell responses, 
and therefore, that in some cases 5’ conjugation does not lead 
to reduced TLR9 potency of CpG.  
Conjugation of CpG ODNs is easily achieved by 
synthesizing, or ordering, custom CpG ODNs containing 
reactive groups on the 3’ or 5’ termini via automated 
phosphoramidite DNA synthesis. In terms of structural 
requirements for CpG ODN conjugation, both 3’ and 5’ 
conjugation of CpG ODNs can yield functional conjugates, 
albeit with reduced potency for some reported 5’ conjugates. 
Recent studies show that 5’ conjugation of CpG does not 
necessarily lead to decreased potency, although other studies 
suggest that a free 5’ end of CpG is vital for immune 
stimulation. Thus, either 3’ or 5’ linkage strategies are 
appropriate for most conjugates. However, TLR9 activity of 
conjugates should be confirmed prior to application. 
 
§ Conclusions 
TLR agonists have demonstrated their therapeutic potential 
in a variety of applications, including approved vaccine 
adjuvants and cancer immunotherapies. However, off-target 
effects, like systemic inflammation, have limited their 
practicality in the clinic. Covalent conjugation of TLR agonists 
to other functional compounds can circumvent these issues by 
generating effective, directed immune responses. Although 
only one TLR-agonist conjugate, Trumenba, has been FDA 
approved, these compounds have shown immense promise and 
additional studies will advance their implementation.  
Production of TLR-conjugates requires careful design to 
ensure efficacy. Through case studies with SAR analysis, TLR-
agonist crystal structure evaluation, and molecular modeling, 
we have learned important considerations when designing TLR 
agonist conjugates. These considerations include the choice of 
agonists, choice of linkage chemistry, slection of conjugation 
sites that maintain agonist activity, and scalability 
considerations. TLR agonist discovery and chemical insights in 
effective TLR agonist conjugation will accelerate the ongoing 
developments at the forefront of vaccine and immunotherapy 
development. 
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